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We have characterized the effects of the antimitotic
drug paclitaxel (TaxolTM) on the Ca2 signaling cascade
of terminally differentiated mouse pancreatic acinar
cells. Using single cell fluorescence techniques and
whole-cell patch clamping to record cytosolic Ca2 and
plasma membrane Ca2-dependent Cl currents, we
find that paclitaxel abolishes cytosolic Ca2 oscillations
and in more than half of the cells it also induces a rapid,
transient cytosolic Ca2 response. This response is not
affected by removal of extracellular Ca2 indicating that
paclitaxel releases Ca2 from an intracellular Ca2
store. Using saponin-permeabilized cells, we show that
paclitaxel does not affect Ca2 release from an inositol
trisphosphate-sensitive store. Furthermore, up to 15
min after paclitaxel application, there is no significant
effect on either microtubule organization or on endo-
plasmic reticulum organization. The data suggest a non-
endoplasmic reticulum source for the intracellular Ca2
response. Using the mitochondrial fluorescent dyes,
JC-1 and Rhod-2, we show that paclitaxel evoked a rapid
decline in the mitochondrial membrane potential and a
loss of mitochondrial Ca2. Cyclosporin A, a blocker of
the mitochondrial permeability transition pore, blocked
both the paclitaxel-induced loss of mitochondrial Ca2
and the effect on Ca2 spikes. We conclude that pacli-
taxel exerts rapid effects on the cytosolic Ca2 signal via
the opening of the mitochondrial permeability transi-
tion pore. This work indicates that some of the more
rapidly developing side effects of chemotherapy might
be due to an action of antimitotic drugs on mitochon-
drial function and an interference with the Ca2 signal
cascade.
Antimitotic drugs are used extensively for the treatment of
cancer. For example, paclitaxel (Taxol) is used in the treatment
of breast and ovarian cancers and for AIDS1-related Kaposi’s
sarcoma, and vinblastine is used in the treatment of Hodgkin’s
disease (1). The mechanism of action of antimitotic drugs, that
leads to cancer cell death, is not clear. It is known that pacli-
taxel stabilizes microtubule dynamics thereby preventing the
proper formation of the mitotic spindle apparatus and arrest-
ing cancer cells at the G2-M phase of the cell cycle (2, 3). While
it is thought that this action of paclitaxel on the cell cycle
machinery precedes an apoptotic response of cells (4, 5), some
recent work has suggested that paclitaxel-induced apoptosis
results from more direct effects of the drug on the mitochon-
dria. In this context paclitaxel has been shown to bind to Bcl-2
(6) and this binding may regulate Bcl-2 effects on the mitochon-
drial permeability transition pore (PTP) (7, 8). Furthermore,
deletion of the loop region of Bcl-2 (which prevents Bcl-2 phos-
phorylation) blocks the apoptotic action of paclitaxel on cancer
cells (9). Other proteins may also be involved in the paclitaxel
effects on mitochondria, such as APAF-1 (10). In isolated mi-
tochondria paclitaxel acts to release cytochrome c (11). This
effect is blocked by cyclosporin A providing further evidence
that paclitaxel directly targets mitochondria, independent of
actions on microtubules.
The effect of antimitotic drugs on microtubule dynamics
would confer drug specificity on actively dividing cancer cells.
However, the actions of these drugs on Bcl-2 and on the mito-
chondria might be expected to be non-selective and affect all
cells. Indeed paclitaxel treatment is associated with serious
side effects, including neuropathy (12) and low white blood cell
counts (13). These side effects occur rapidly, appear to be due to
drug action on terminally differentiated cells, and are slowly
reversible. Thus it is unlikely that these side effects are medi-
ated by either mitotic block or apoptosis. Given that the clinical
use of antimitotic drugs is limited by these side effects, under-
standing the mechanisms by which these drugs act is an im-
portant step toward optimizing the therapeutic benefits.
In our studies, on terminally differentiated epithelial cells,
we now show rapid actions of paclitaxel on the cytosolic Ca2
signal that can be accounted for by effects of paclitaxel on the
PTP of the mitochondria. Given the universality of Ca2 sig-
naling, it is likely that this action of paclitaxel accounts for
some of the side effects of antimitotic drugs.
EXPERIMENTAL PROCEDURES
Cell Preparation—Male outbred albino mice (25 g) were killed by
cervical dislocation and the pancreas dissected. Mouse pancreatic aci-
nar cells were prepared by collagenase (Worthington, CLSPA, Lorne
Labs.) digestion at 33 °C for 7 min as previously described (14). Cells
were plated onto poly-L-ornithine (Sigma, United Kingdom)-coated
dishes and were used within 3 h of isolation from the animal.
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Patch Clamp—Standard whole cell patch clamp techniques (15) were
employed and all experiments were carried out at room temperature
(21 °C). Pipettes had a resistance of 3–6 M (pipette puller, Brown
and Flaming). After breaking through to the whole cell configuration
pipettes had a measured, but uncompensated, series resistance of
10–20 M. The pipette solution contained (mM): 140 KCl, 1 MgCl2, 2
Na2ATP, 0.01 EGTA, (0.05 calcium green (Molecular Probes, Eugene,
OR), 10 HEPES KOH, pH 7.2. The extracellular solution contained
(mM) NaCl 135, KCl 5, MgCl2 1, CaCl2 1, glucose 10, NaOH-HEPES 10,
pH 7.4. In the Ca2-free solution, used in the experiments of Fig. 2, no
Ca2 was added. Cells were held at a membrane potential of 30 mV
and currents were sampled by an A/D converter (EPC-9, HEKA) at 2
KHz. In most experiments Ins(2,4,5)P3 (gift from Professor R. Irvine,
Cambridge, UK) was added to the pipette solution (10 M) to establish
trains of Ca2 spikes. These spikes have previously been shown to
result from InsP3-dependent Ca
2 release in the secretory pole (16).
Fluorescence Imaging—Ca2 imaging experiments were performed
as previously described (17). Briefly, inclusion of 40–50 M Calcium
Green in the pipette solution allowed imaging of the cytosolic Ca2
signal. Cells were illuminated at 488 nm (Coherent Innova 70) and
imaged through a Nikon 40 UV, 1.3NA, oil immersion objective
through a 510-nm long pass filter. Full frame images (128  128 pixels)
were captured on a cooled CCD camera (70% quantum efficiency, 5
electrons readout noise; MIT, Lincoln Laboratories) with a pixel size of
200 nm at the specimen and at rates of up to 500 Hz. After recording to
computer, the data were analyzed with custom software with bleach
correction routines and appropriate smoothing. Images were displayed
as F/Fo images (100  (F  Fo)/Fo), where F is the recorded fluores-
cence and Fo was obtained from the mean of 20 sequential frames where
no activity was apparent.
Single-cell Fluorescence Measurement—Cells were loaded with acte-
toxymethyl esters of various fluorescent probes (Molecular Probes) and
the fluorescent signal measured from single cells with a Cairn Dual
Emission Fluoresence System (Cairn Research, Faversham, UK). Meas-
urement of mitochondrial membrane potential (m) was carried out
using the dye JC-1 loaded at a concentration of 1 M for 20 min at room
temperature (22 °C). The dye was excited at a wavelength of 488 nm
and the emitted light collected at 590 and 530 nm. The ratio of red (590
nm) to green (530 nm) gives an index of the mitochondrial membrane
potential: the higher the mitochondrial potential the greater proportion
of JC-1 aggregates in the mitochondria, the greater the intensity of the
red light signal and so with active mitochondria we see a relatively high
ratio of 590/530 nm (18). To measure mitochondrial Ca2 signals we
used Rhod-2AM at a concentration of 10 M loaded at 37 °C for 40 min.
This protocol specifically loaded the dye into the mitochondria as judged
by the overlapping fluorescent signal from the mitochondrial dye Mit-
ofluor (Fig. 6). In these experiments data are presented as F/Fo, where
F is the recorded fluorescence and Fo was measured before drug
application.
Estimates of Intracellular Paclitaxel Concentrations—In our experi-
ments we used 10–20 M paclitaxel applied to the bathing solution of
the cells. To estimate the intracellular concentration reached over a
period of 10 min we used Oregon Green-conjugated paclitaxel (Molec-
ular Probes) and imaged intracellular fluorescence using a Zeiss LSM
510 confocal microscope. The intracellular fluorescence was measured
over time within an 8-m spot centered on the cell with an optical
section of 1 m. A calibration curve was made using a range of Oregon
Green paclitaxel concentrations and recording the fluorescence signal
as above. For two independent experiments we obtained a value of
322.5 nM as the peak intracellular concentration reached over 10 min.
This value represents an upper limit for the cytosolic concentration of
the drug, as it would be expected to bind to microtubules.
Ca2 Flux Experiments—Hepatocytes were isolated from livers of
male Wistar rats and then permeabilized by incubation with saponin
(10 g/ml) in cytosol-like medium containing 140 mM KCl, 20 mM NaCl,
2 mM MgCl2, 1 mM EGTA, 20 mM Pipes (pH 7 at 37 °C). The cells were
washed and resuspended (10 million cells/ml) in cytosol-like medium
supplemented with CaCl2 (free [Ca
2]  200 nM), ATP (7.5 mM), car-
bonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP, 10 M), and
45Ca2 (7.5 Ci/ml) (19). FCCP was used in these experiments to ex-
clude Ca2 flux from mitochondria. After 5 min at 37 °C, during which
the intracellular stores loaded to steady-state with 45Ca2, thapsigargin
(1.25 M) was added to inhibit further Ca2 uptake together with
paclitaxel (20 M) or its solvent (Me2SO) and either a maximal (5 M) or
submaximal (100 nM) concentration of Ins(1,4,5)P3. After a further 5
min, the incubations were terminated by rapid filtration and the 45Ca2
contents of the stores determined. After correction for the 45Ca2 non-
specifically bound to the cells (determined by addition of 10 M iono-
mycin), the 45Ca2 contents of the stores were expressed as percentages
of the control 45Ca2 content.
Immunocytochemistry—Cells were washed quickly in PBS (including
calcium and magnesium) and then in K-Pipes buffer (K-Pipes 80 mM,
EGTA 5 mM, MgCl2 2 mM, pH 6.5). Cells were then fixed in 4%
paraformaldehdye in K-Pipes buffer for 30 min and permeabilized in
0.1% Triton X-100 in PBS for 5 min. After a 1-h block in 2% donkey
serum plus 2% fish skin gelatin in PBS, cells were incubated in primary
antibody (-tubulin mouse monoclonal, clone TUB 2.1, Sigma, UK) for
1 h. After washing, a secondary antibody (donkey anti-mouse Fab
fragment, Jackson Immunoresearch, West Grove, PA) conjugated to a
fluorescein isothiocyanate fluorphore was applied for 30 min. The im-
ages of Fig. 6 were obtained with a Zeiss LSM510 confocal microscope
with a 63 planacromat oil immersion lens and excitation light pro-
vided by an argon and a HeNe laser. The emitted light collected at the
indicated wavelengths. Confocal sections (1 m in depth) were obtained
in the mid-section of the cells and image overlays were produced with
proprietary Zeiss software.
RESULTS
We have previously used the whole cell patch clamp method
to record the activation of Ca2-dependent chloride currents
(Cl(Ca)) in single mouse pancreatic acinar cells (16). The Cl(Ca)
current is commonly used as an indirect measure of cytosolic
Ca2 and is a particularly good index of the small subplasmale-
mal Ca2 signals that occur in the apical pole of polarized
epithelia (17). Fig. 1 shows the typical effects of paclitaxel on
the whole cell Cl(Ca), currents in a single pancreatic acinar cell.
In a cell stimulated with Ins(2,4,5)P3 to produce trains of Ca
2
spikes (16), paclitaxel induced a rapid increase in the Cl(Ca)
current followed by an abolition of the spike response (n 
14/26, Fig. 1A). In the other 12 cells paclitaxel led to a gradual
loss of the Cl(Ca) current spikes (Fig. 1B). Applied alone pacli-
taxel had no effect (n 3 cells, Fig. 1C) and Me2SO, the solvent
in which paclitaxel was dissolved, at 1% (v/v) (a 5–10 greater
concentration than that used in the paclitaxel experiments)
had no significant effect on the current spikes (Fig. 1D).
These data indicate that paclitaxel can, in many cells, pro-
mote a rapid activation of the Cl(Ca) current. Since the Cl(Ca)
channels are primarily under the control of cytosolic Ca2 (20)
this suggests that paclitaxel elicits a Ca2 signal. To test this
directly we carried out Ca2 imaging experiments using the
Ca2-sensitive fluorescent dye Calcium Green introduced into
the cell cytosol via infusion through the solution of the patch
pipette (21). We further probed the possible source of the Ca2
signal induced by paclitaxel by removing extracellular Ca2 in
these experiments. Fig. 2 shows a typical response, the infusion
of Ins(2,4,5)P3 resulting in the induction of small, short-lasting
Ca2 spikes in the apical region of the cell (indicated secretory
pole, SP, in Fig. 2). Application of 10 M paclitaxel induced a
rapid Ca2 response that spread from the apical region to all
regions of the cell (n  5/6 cells). In these experiments we were
limited to capturing images over an 80-s period. However, a
second series of images, captured later in the experiment,
showed no evidence of a Ca2 signal, indicating that the pacli-
taxel-evoked Ca2 rise was transient and the local Ca2 spikes
were abolished (data not shown). This is entirely consistent
with the data shown in Fig. 1A. Since there is no extracellular
Ca2 we conclude that the paclitaxel induced Ca2 response
must originate from an intracellular Ca2 store.
The major Ca2 store in pancreatic acinar cells is in the
endoplasmic reticulum (ER) where Ca2 is released in an IP3-
dependent manner (22, 23). To test if paclitaxel might be acting
directly on IP3-dependent stores we utilized the permeabilized
hepatocyte preparation where the Ca2 stores were preloaded
with 45Ca2 and the loss of radiolabeled Ca2 in response to
Ins(1,4,5)P3 was measured (19). The data in Table I show that
a saturating concentration of 5 M Ins(1,4,5)P3 releases about
30% of the Ca2 from the store and that this response is
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unaffected by the presence of paclitaxel. At an intermediate
concentration of Ins(1,4,5)P3 (100 nM) about 20% of the store
Ca2 content is released and again paclitaxel has no significant
effect on this. We conclude that the intracellular Ca2 store
affected by paclitaxel is not likely to be IP3-dependent. How-
ever, our data do not exclude the possibility that, while pacli-
taxel may not act directly on IP3-dependent release of Ca
2, it
may act indirectly by physically changing the store morphology
and this in turn may affect store behavior. In this context we
have previously shown that microtubule depolymerizing
agents have dramatic effects on Ca2 signaling by locally and
rapidly reorganizing the ER (24). We therefore went on to study
the possible effects of paclitaxel on microtubular and ER
organization.
To measure any effects of paclitaxel on microtubule and ER
organization we carried out experiments to immunolocalize
TABLE I
IP3-dependent Ca
2 release is unaffected by paclitaxel
45Ca2 was preloaded into the Ca2 stores of permeabilized hepato-
cytes. The figures show the 45Ca2 remaining after the various condi-
tions, expressed as % of the total content. 5 M Ins(1,4,5)P3 is a satu-
rating concentration and the entire Ins(1,4,5)P3-dependent Ca
2 store
is emptied (19). In our experiments this represents about 30% of the
total loaded 45Ca2. With 100 nM Ins(1,4,5)P3 about 20% of the total
store is emptied. In all conditions paclitaxel had no significant effect on
Ins(1,4,5)P3-dependent release. The
45Ca2 remaining after application
of 5 M Ins(1,4,5)P3 is presumed to represent Ca
2 uptake into
Ins(1,4,5)P3-independent pools such as secretory vesicles and endo-
somes. Data are expressed as the mean  S.E.
Control Paclitaxel
100 107  4
100 nM IP3 83  1 81  3
70  3 72  4
FIG. 1. Paclitaxel rapidly activates
the Cl(Ca) current in whole cell patch
clamp recordings of single isolated
mouse pancreatic acinar cells. Cells
were held under voltage clamp at a mem-
brane potential of 30 mV. A, when
Ins(2,4,5)P3 (10 M) was included in the
patch pipette solution trains of spikes
(downward deflections in the current, i.e.
the outward movement of Cl) were in-
duced, and in the majority of cells the
application of paclitaxel (10–20 M) rap-
idly promoted a transient increase in cur-
rent amplitude and broadened the spike
width. B, in other cells paclitaxel induced
a rapid abolition of spiking. C, applied
alone to the bathing solution paclitaxel
had no effect on the currents; and D, the
Me2SO carrier applied alone had no effect
on spiking.
FIG. 2. Paclitaxel induces a rapid
global Ca2 response. In these experi-
ments cells were filled with the Ca2-sen-
sitive dye calcium green and IP3 (10 M)
and fluorescent images collected every
200 ms. The phase image (upper left)
shows the orientation of the cell with the
apical (secretory) pole (SP) on the left-
hand side and the basal pole (BP) on the
right. This cell was part of a 3-cell cluster
and the other cells can be seen on the left.
Image a was obtained during a quiescent
period and shows low Ca2 (pseudocolor
blue) across the cell. The box in this image
shows the area used in producing the av-
erage fluorescent signal versus time
shown in the graph at the bottom of the
figure. Images b, d, and f were obtained at
the peak of the Ca2 spikes and illustrate
that the signal does not spread beyond
the secretory pole region. In contrast, im-
age h was obtained at the peak of the
paclitaxel-induced response and shows a
large Ca2 rise (pseudocolor red) globally
across the whole of the cell.
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-tubulin and to image the fluorescent probe, ER tracker, re-
spectively. Standard microtubule-preserving techniques were
used to fix the acinar cells (K-Pipes buffer) and we probed with
a monoclonal antibody against -tubulin. We then imaged clus-
ters of acinar cells taking confocal sections through the cluster
of cells at various depths. For clarity, Fig. 3 shows confocal
sections only through the lower, middle, and the upper parts of
the cell clusters. In the phase images shown the apical domain
is seen in the central part of the cell clusters and is delineated
by the presence of the phase-dark secretory granules. In control
cells an extensive network of microtubules was observed with
predominance in the apical domain, the region presumed to
contain the microtubule organizing centers (25) (Fig. 3). Appli-
cation of paclitaxel (20 M) did not dramatically alter this
pattern of staining although the impression was that after 5
min treatment there was a structural reorganization that led to
a criss-cross pattern of microtubules in the basal pole (two
independent preparations). To test if this possible rearrange-
ment of the microtubular system has any effect on the ER
distribution we used ER tracker that has the key advantage of
allowing visualization of the ER in single live cells. Fig. 4 shows
a typical experiment with the ER tracker fluorescence excluded
from the granular region of the secretory pole and from the
nucleus. This distribution of fluorescence is consistent with the
distribution of the ER as visualized with immunolocalization of
the ER-resident protein calreticulin (24, 26). To determine any
changes in the ER distribution we recorded the average fluo-
rescent signal in a 5-m diameter region in the apical (secre-
tory pole) and divided this by the average signal in a 5-m
diameter region in the basal pole. The ratio of secretory pole to
basal pole fluorescence (SP/BP fluorescence ratio) did not
change in control cells (circles, n 7 independent cells) and did
not change in the presence of 10 M paclitaxel (triangles, n 10
independent cells). We conclude that paclitaxel does promote
changes in the microtubular system but, at least over this time
frame, there is no reorganization of the ER. These observations
are consistent with early observations, in other cell types, of
paclitaxel effects on microtubules and ER organization (27).
Another intracellular Ca2 store, significant in many cell
types, is the mitochondria. In pancreatic acinar cells mitochon-
dria have been shown to contain low levels of Ca2 at rest, but
to rapidly take up Ca2 during IP3-evoked Ca
2 responses (28).
If paclitaxel acted to release Ca2 from mitochondria this
would be consistent with the cytosolic Ca2 responses we ob-
served. We therefore set out to determine possible effects of
paclitaxel on mitochondria. If paclitaxel were stimulating a
route of Ca2 exit from the mitochondria there are three known
mechanisms where it might act. These are: (a) the PTP; (b)
Na-dependent efflux; (c) Na-independent efflux (29). Ca2
efflux through any of these pathways would be expected to
affect the mitochondrial membrane potential (m). To record
this we utilized the potential-sensitive probe JC-l. We observed
a rapid decrease in the ratio of emitted light collected at 590
and 530 nm on addition of the mitochondrial uncoupler FCCP
(1 M, Fig. 5A) that represents a drop in m. In separate
experiments, 10 M paclitaxel (n  8/11 cells, Fig. 5B) induced
a decrease in m.
FIG. 3. Paclitaxel does not dramatically change the microtu-
bule distribution. In control cells (upper panel) a 3-cell cluster is
shown with single confocal image planes taken at the bottom (2 m
from the bottom of the coverslip), middle, and top (2 m down from
the top of the cells). The images show a concentration of microtubules in
the secretory pole (central granular region) which is where the micro-
tubule organizing centers are thought to be. From the secretory pole
microtubules radiate in an apparently disordered array. After 5 min
(middle panel) and 15 min (lower panel) treatment with paclitaxel there
is no dramatic effect on this microtubule organization although there is
an apparent change in the morphology of microtubules in the basal pole.
FIG. 4. Paclitaxel does not affect the distribution of the endo-
plasmic reticulum. A, cells were loaded with ER tracker, a fluorescent
probe that inserts into intracellular membranes. The fluorescent signal
observed shows a widespread distribution across the cell with exclusion
from the nucleus and secretory granules. B, after paclitaxel treatment
no change in the pattern of fluorescence was observed. C, the signal was
quantified by measuring the average fluorescence in a 5-m diameter
region in the secretory pole (SP) and ratioing this to a 5-m diameter
region in the basal pole. Individual points on the graph were obtained
from 7 cells (control, circles) and 10 cells (paclitaxel, triangles) with a
minimum of 3 cells for any data point.
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To determine if these effects of paclitaxel on the m might
be associated with a loss of mitochondrial Ca2 we carried
out experiments to directly measure mitochondrial re-
sponses. We used Rhod-2/AM, a Ca2-sensitive dye that can
be specifically loaded into the mitochondria. To verify that
our dye loading protocol led to a specific loading of the mito-
chondria we carried out control experiments where we also
loaded the cells with Mitofluor Green/AM, a mitochondrial
specific dye (30). The excitation/emission wavelengths of
these dyes are widely separated and we ensured, using ex-
periments with only a single dye, that there was no “bleed”
from one fluorescence channel to the other. We then took
confocal images of Rhod-2 and Mitofluor Green fluorescence
in the same cell. The results indicated that Rhod-2 and Mit-
ofluor Green were loaded into the same cellular compartment
with a characteristic distribution (Fig. 6) similar to that
previously described for mitochondria in these cells (31). This
result indicates that the Rhod-2 signal we record from single
cells is predominantly from the mitochondria.
First we measured the Rhod-2 response following stimula-
tion of the cells with the agonist acetylcholine. In 3/4 cells, 100
nM acetylcholine induced an increase in the mitochondrial Ca2
as measured by an increase in the Rhod-2 fluorescence (Fig.
7A). Subsequent addition of 10 M paclitaxel induced a drop in
mitochondrial Ca2 (n  4/4 cells) and a further decline was
seen with the addition of 1 M FCCP (n  3/3 cells). In cells not
stimulated with agonist the measured Rhod-2 response from a
single cell showed a rapid decline in response to paclitaxel (n 
5/8 cells) and a further decline in response to 1 M FCCP (n 
6/7 cells, Fig. 7B). From these results we conclude that pacli-
taxel does induce a loss of Ca2 from the mitochondria. To test
for the possible route of exit of Ca2 we pretreated the cells
with cyclosporin A (10 M), a drug that binds to cyclophilin D
and leads to the block of the mitochondrial PTP. The subse-
quent addition of paclitaxel either failed to induce any decrease
in the Ca2 signal (n 5/8) or slowed the rate of decrease of the
Ca2 signal (n  3/8, Fig. 7C). To quantify these effects we
measured the paclitaxel-induced decrease in Rhod-2 fluores-
cence 30 s after drug application in the absence and presence of
cyclosporin A (Fig. 7D). An FCCP induced decrease in Ca2was
still observed after pretreatment with cyclosporin A (n  6/6),
presumably because Ca2 can still exit via other efflux
mechanisms.
If the paclitaxel action on the cytosolic Ca2 signal was
mediated by an effect on mitochondria then cyclosporin A
might be expected to protect the cell from paclitaxel action. We
tested this first with 10 M cyclosporin applied during a train of
spikes induced by Ins(2,4,5)P3. However, the drug had effects
alone and acted to increase spike activity (n  3, data not
shown). A lower concentration of cyclosporin A (5 M) was
therefore used. This had no effect on spike activity. After treat-
ing the cells for 5 min in cyclosporin A, we then applied pacli-
taxel. In contrast to control cells paclitaxel did not abolish
spiking and had only a small transient effect on the signal (n 
3/4 cells, Fig. 8). This data supports our hypothesis that the
primary action of paclitaxel on the Ca2 signal cascade is
mediated via an effect on the PTP.
DISCUSSION
The major finding of this study is that the anticancer drug
paclitaxel rapidly releases Ca2 from the mitochondria of pan-
creatic acinar cells. Although the mechanism underlying this
effect is not completely clear, the ability of cyclosporin A to
block the Ca2 release points to an effect of paclitaxel on the
PTP. We suggest that paclitaxel acts by partially opening the
PTP. Ion flow through the PTP then causes a drop in mitochon-
drial membrane potential and a release of mitochondrial Ca2.
FIG. 5. Paclitaxel depolarizes the mitochondrial membrane
potential as measured with the fluorescent dye JC-1. Cells were
loaded with JC-1 and then viewed under the microscope with an exci-
tation light of 488 nm; the mitochondria appeared red and the cytosol
green. A high 590/530 nm ratio indicates active, polarized mitochon-
dria, and a drop in the ratio indicates a drop in 	m. A, addition of
FCCP (1 M) rapidly depolarizes the mitochondrial potential. B, adding
paclitaxel (10–20 M) had a similar effect.
FIG. 6. Rhod-2 fluoresence co-localizes with Mitofluor fluores-
cence. Imaging of Rhod-2 (Ca2-sensitive dye) and Mitofluor (a mito-
chondrial specific fluorescent probe) in a cluster of living acinar cells
shows the characteristic distribution of mitochondria around the secre-
tory pole. In a mid-confocal section through the cells, Rhod-2 clearly
co-localizes with the Mitofluor fluorescence (overlay) indicating the our
dye loading conditions for Rhod-2AM selectively loads the mitochon-
dria. The Rhod-2 signal can therefore be used as a measure of mito-
chondrial Ca2.
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These effects may underlie some of the side effects of antimi-
totic drug treatments.
Effects of paclitaxel on mitochondria have been noted before.
Paclitaxel phosphorylates Bcl-2 in cancer cells and induces
apoptosis, possibly by acting on the PTP (4–6). Andre et al. (11)
have shown that paclitaxel induces cytochrome c release from a
preparation of isolated mitochondria. The same study also
showed that this cytochrome c release was blocked by pretreat-
ment with cyclosporin A. These direct or indirect actions on
mitochondria (32, 33) may in turn generate the cytosolic Ca2
responses we observe.
Our measurements of the effects of paclitaxel on the
Ins(2,4,5)P3-induced spikes indicate that in more than 50% of
cells the drug induces a release of Ca2 from an intracellular
store followed by abolition of the spikes. In the remaining cells
paclitaxel led to a rapid abolition of spike activity. Why does
the drug have these different actions? The same action on
mitochondria may underlie both effects, with the difference
being heterogeneity of mitochondrial Ca2 loading. In cells
where the mitochondria were replete with Ca2, paclitaxel-
induced opening of the PTP would elicit a cytosolic Ca2 signal.
However, in cells where the mitochondria were less well loaded
the expected cytosolic Ca2 signal may be too small to detect.
Pharmacological block of mitochondrial function has been
shown to enhance cytosolic Ca2 responses in astrocytes (30)
and acinar cells (31). These effects may be equivalent to the
transient cytosolic Ca2 response to paclitaxel we see in the
acinar cells. In all of our experiments we observed an eventual
abolition of the Ca2 spikes. This appears to conflict with the
enhancement of responses described above. However, block of
mitochondrial function has been shown to inhibit Ca2 re-
uptake into Ca2 stores (34) and since the Ca2 spikes in
acinar cells are dependent on cycles of Ca2 release and Ca2
uptake this effect would lead to a loss of spiking. Mitochondria
are physically held in close proximity to sites of Ca2 release
(35) and therefore are in a good position to modulate both Ca2
release and Ca2 reuptake (36).
The actual concentration of intramitochondrial Ca2 results
from a balance of Ca2 uptake by the uniporter and a variety of
Ca2 efflux mechanisms (29). During periods of cell stimulation
where the cytosolic Ca2 is high, the mitochondrial Ca2 rises
(35). After stimulation, the intramitochondria Ca2 returns back
to lower levels. It is not clear if the PTP contributes to the
endogenous mechanisms of Ca2 efflux from mitochondria but it
may be important in processes of charge balance that would be
required for Ca2 exit. What is clear is that a drug-induced
opening of the PTP, as we postulate for the action of paclitaxel,
would both reduce the mitochondrial potential and lead to Ca2
efflux. This would modify the cytosolic Ca2 responses, as we
show in this paper. In addition, since the intramitochondrial
Ca2 signal has been shown to actively regulate mitochondrial
functions such as Ca2-dependent dehydrogenases (37), these
would be expected to be affected by paclitaxel, and would lead to
a loss of ATP production and the subsequent compromise of many
other cell functions.
Our experiments indicate that the PTP plays a role in the
paclitaxel-mediated responses but exactly how the PTP is af-
fected is unclear. One possibility, put forward by Andre et al. (11)
to explain paclitaxel effects on isolated mitochondria, was that
the mitochondria might contain tubulin within their structure. In
this model the binding of paclitaxel to this tubulin might influ-
ence PTP function either through a tubulin interaction with the
voltage-dependent anion channel present on the outer mitochon-
drial membrane (7) or through the adenine nucleotide trans-
porter at the inner membrane, both of which are thought to form
the PTP. While this is an attractive hypothesis, other experi-
ments clearly indicate Bcl-2 as a possible target for paclitaxel (6,
9). Bcl-2 is resident in the mitochondrial membrane and it is
thought that drug-induced phosphorylation may lead to PTP
FIG. 7. Mitochondrial Ca2 is de-
creased by paclitaxel and by FCCP.
In these experiments cells were loaded
with Rhod-2 under exactly the same con-
ditions as in experiments of Fig. 6. A,
single cell fluorescence measurements
showed an increase in mitochondrial
Ca2 on addition of 100 nM acetylcholine
and a drop in Ca2 on addition of pacli-
taxel to the bathing solution and a further
drop when FCCP was added. B, in un-
stimulated cells the same paclitaxel and
FCCP induced drop in Ca2 was observed.
C, pretreatment with cyclosporin A inhib-
ited the paclitaxel effect but did not block
FCCP-induced reductions in Ca2. D,
graph showing the mean ( S.E., n  8)
drop in Rhod-2 fluorescence induced by
paclitaxel alone, or in the presence of cy-
closporin A. The difference in the two
points was significant at p 
 0.05 (Stu-
dent’s t test).
FIG. 8. Pretreatment with cyclosporin A (5 M) prevents the
paclitaxel-induced effects on Ca2 spiking. Cl(Ca) current spikes
induced with Ins(2,4,5)P3 were recorded in whole-cell patch clamp re-
cordings of single isolated mouse pancreatic acinar cells and cyclosporin
A applied to the bathing solution. Subsequent application of paclitaxel
did not abolish spiking (n  3/4).
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opening and the triggering of cyctochrome c release from mito-
chondria (9). There are further complications in understanding
the effects of paclitaxel on the PTP since it has been shown that
at least two possible states of PTP opening are possible. In both
states cytochrome c release is observed but in only one of the
states is a change in 	m seen (39, 40). In one study the change
in 	m was associated with mitochondrial swelling and was
specifically induced by high, but not low, concentrations of Bax,
the proapoptic agent (39). In another study different states were
differentially induced by A23187 or arachadonic acid and cell
death was only associated with the changes in 	m (40). We
show that paclitaxel induces a rapid and dramatic change in
	m, Andre et al. (11) showed paclitaxel-induced mitochondrial
swelling, and combined, these data suggest paclitaxel acts to
induce a more sustained opening of the PTP. This would lead to
paclitaxel-induced apoptosis as shown in cancer cells (10). How-
ever, in treating cancers paclitaxel is applied as a short infusion
at a high concentration (41) and, in terminally differentiated
cells, this transient exposure to the drug may disrupt mitochon-
drial function but not trigger cell death.
Although our experiments indicate that the effects of pacli-
taxel on the Ca2 signal are due to a rapid action on mitochon-
dria, we cannot completely rule out other effects, on either the
microtubules or the ER, that may contribute to the Ca2 re-
sponse. The microtubule distribution appears little effected by
paclitaxel over the time course we studied, but there may be
more subtle effects on signaling cascades that might lead to
modification of the Ca2 response. For example, it has been
shown that microtubule stabilization leads to a rapid activation
of Rac1 (38) and this could conceivably influence Ca2 release
in our system. Although we do not see any effects of paclitaxel
on ER distribution, ER integrity (42) or positioning (27) may be
disrupted in a way not resolved by our techniques.
We used 10–20 M paclitaxel, which is a similar concentra-
tion to that used in other studies (e.g. Ref. 11). It is also in the
range of the peak plasma concentrations reached in the clinical
situation during treatment regimes. For example, a typical
treatment of a 6-h infusion of Taxol at 275 mg/m2 leads to a
peak plasma concentration of 8.11 M (42). The concentrations
we use are therefore in this clinically relevant range. However,
they are higher than the concentrations of paclitaxel (10–100
pM) used to show effects of mitotic block in cultured cells (2).
Paclitaxel accumulates in cells and tissues. For example during
long-term incubation with 100 pM, intracellular concentrations
of 40.5 M are reached (2). We have directly measured intra-
cellular paclitaxel concentrations, using a fluorescent conju-
gate and show that the acute exposure of the cells to paclitaxel
results in a very low initial uptake into the cells (see “Experi-
mental Procedures”). Although it remains to be determined if
the pharmacokinetic properties of the fluorescent paclitaxel are
the same as the native drug. We conclude that the concentra-
tions of paclitaxel we used in our study are relevant to the
clinical use of the drug and therefore the acute effects we
observe may underlie some of the drug side effects.
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